Loading...
•
Jun 30, 2021
Ovid Therapeutics Q2 2021 Earnings Report
Reported financial results for the second quarter of 2021 and provided an overview of recently announced leadership appointments.
Key Takeaways
Ovid Therapeutics reported its Q2 2021 financial results, highlighting a strong cash position of $212.2 million and recent appointments to the company's leadership team aimed at advancing neuroscience programs. The company's operating expenses were $14.3 million, but non-GAAP adjusted operating expenses were $10.0 million, within the company's guidance.
Ended Q2 2021 with cash and cash equivalents of $212.2 million.
Appointed experts with neuroscience development and investment acumen to the board and advisory team.
Executive appointments deepen management capability of senior team.
Two, pivotal Phase 3 clinical studies of soticlestat for Dravet syndrome and Lennox-Gastaut syndrome, operated and funded by Takeda, are expected to commence in 2021.
Forward Guidance
Ovid expects operating expenses (less non-recurring expenses and non-cash expenses) to remain in the $8.0 - $10.0 million range for the remaining quarters of 2021.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...